查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1494902

到 2030 年放射性皮肤炎市场预测：按产品、阶段、分销管道和地区进行的全球分析

Radiodermatitis Market Forecasts to 2030 - Global Analysis By Product (Topical, Oral Drugs and Dressings), Stage (Mild, Moderate and Severe), Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球放射性皮肤炎市场规模为 4.583 亿美元，预计到 2030 年将达到 6.284 亿美元，预测期内复合年增长率为 5.4%。

放射性皮肤炎是一种由放射线治疗引起的皮肤病，常见于癌症患者。症状包括皮肤发红、发炎、脱皮，有时甚至溃疡。严重程度从轻度到重度不等，会影响生活品质并中断癌症治疗。有效的治疗包括局部治疗、敷料和减轻症状的预防措施。

根据美国国家癌症美国(NCI) 的数据，约 95% 接受放射线治疗的患者会出现放射性皮肤炎。

癌症增加

癌症发生率的增加是放射性皮肤炎市场的关键驱动因素。癌症是全世界死亡的主要原因，放射治疗作为重要治疗方法的使用正在增加。随着越来越多的人接受各种癌症的放射线治疗，常见副作用放射性皮肤炎的盛行率也增加。对放射性皮肤炎管理解决方案（包括皮肤护肤产品和治疗）的需求不断增长，正在推动市场成长并推动该领域的创新和投资。

治疗费用高

与治疗放射性皮肤炎相关的费用，包括药物、护肤产品和支持性护理，给患者带来了经济负担。此外，放射治疗的累积费用也加剧了经济负担。对许多患者来说，支付治疗费用的能力是一个关键问题，尤其是那些保险不足或经济拮据的患者。这种障碍可能会限制获得最佳治疗和遵守治疗方法，从而影响患者的整体治疗结果和市场成长。

医疗基础设施的成长

特别是在新兴国家，医疗保健设施的改善正在改善放射性皮肤炎患者获得诊断、治疗和支持性护理的机会。随着专科诊所、放射肿瘤中心、皮肤科的开设，放射性皮肤炎患者可以得到及时、全面的治疗。此外，增强的基础设施将促进研究和开发活动，并促进创新治疗方法和护肤产品的推出，最终推动市场成长并改善患者的治疗效果。

替代疗法

替代疗法对放射性皮肤炎市场构成威胁，因为它们提供自然和非药物治疗来控制放射治疗与皮肤相关的副作用。从草药疗法到同类疗法疗法，这些治疗方法可能会吸引寻求更温和、更全面的方法的患者。因此，它可能会转移人们对传统医疗干预措施和药物的注意力和需求，从而影响竞争力和市场成长。

COVID-19 的影响：

COVID-19 大流行扰乱了医疗保健服务、推迟了非紧急治疗并将重点转移到了病毒控制上，从而影响了放射性皮肤炎市场。这导致放射性皮肤炎的诊断和治疗暂时放缓。然而，一旦医疗保健系统稳定并优先考虑癌症治疗，由于被压抑的需求和放射性皮肤炎治疗的持续进步，市场预计将復苏。

在预测期内，外用药物领域预计将是最大的。

在预测期内，局部用药预计将成为放射性皮肤炎市场中最大的部分。这一增长是由多种因素推动的，包括局部治疗的便利性、使用的简便性以及管理放射性皮肤炎症状的有效性。此外，局部製剂的进步，包括新型化合物和递送系统的开发，正在提高治疗效果。随着对患者舒适度和用药依从性的日益关注，预计未来几年对局部治疗的需求将显着增长。

线上药局领域预计在预测期内复合年增长率最高

预计线上药局领域在预测期内将见证放射性皮肤炎市场的良好成长。这种快速成长的主要驱动力是越来越多地采用电子商务平台购买药品。便利性、可近性和广泛的产品选择等因素促进了这一领域的快速成长。此外，远端医疗和数位医疗服务的趋势进一步推动了透过线上药局治疗放射性皮肤炎的需求，推动市场扩张。

占比最大的地区：

由于亚太地区人口众多、感染疾病流行率不断上升以及人们对疫苗接种益处的认识不断提高，预计亚太地区将占据疫苗佐剂市场的最高市场占有率。此外，政府措施、对医疗基础设施的投资、主要市场参与者的存在以及不断扩大的生物製药产业都有助于市场成长。亚太地区对创新研发的关注和有利的法规环境进一步推动了该地区的需求。

复合年增长率最高的地区：

预计在预测期内，亚太地区的放射性皮肤炎市场复合年增长率最高。这项预测是由于多种因素造成的，包括癌症发生率上升、放射线治疗采用率增加、医疗基础设施扩大以及对放射性皮肤炎管理认识的提高。此外，医疗保健技术的进步和政府改善癌症治疗的倡议预计将推动该地区的市场成长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球放射性皮肤炎市场：副产品

  • 外用
    • 皮质类固醇
    • 亲水霜
    • 外用抗生素
    • 其他外用药物
  • 口腔医学
  • 敷料
    • 纱布浸入蜂蜜中
    • 亲水胶体敷料
    • 水凝胶敷料
    • 防刺膜
    • 硅胶涂层敷料
    • 其他敷料

第六章全球放射性皮肤炎市场：依阶段

  • 温和的
  • 中等的
  • 严重

第七章全球放射性皮肤炎市场：按分销管道

  • 医院药房
  • 零售药房
  • 网路药房

第八章全球放射性皮肤炎市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司概况

  • 3M Company
  • Acelity LP Inc.
  • Alliqua Biomedical, Inc.
  • B. Braun Melsungen AG
  • BMG Pharma SpA
  • Cardinal Health, Inc.
  • Coloplast A/S
  • Convatec Group Plc
  • DermaRite Industries, LLC
  • GlaxoSmithKline plc
  • Hollister Incorporated
  • Integra Lifesciences Holdings Corporation
  • Medline Industries, Inc.
  • MiMedx Group, Inc.
  • Molnlycke Health Care AB
  • Pfizer Inc.
  • Radiation Products Design Inc.
  • Smith & Nephew plc
  • Stratpharma AG
Product Code: SMRC26422

According to Stratistics MRC, the Global Radiodermatitis Market is accounted for $458.3 million in 2024 and is expected to reach $628.4 million by 2030 growing at a CAGR of 5.4% during the forecast period. Radiodermatitis is a skin condition caused by radiation therapy, commonly experienced by cancer patients. It manifests as redness, irritation, peeling, and sometimes ulceration of the skin. The severity ranges from mild to severe, impacting the quality of life and potentially disrupting cancer treatment. Effective management includes topical treatments, dressings, and preventive measures to mitigate symptoms.

According to the National Cancer Institute (NCI), radiation dermatitis occurs in approximately 95% of patients receiving radiation therapy.

Market Dynamics:

Driver:

Increasing incidence of cancer

The increasing incidence of cancer serves as a significant driver in the radiodermatitis market. With cancer being a leading cause of mortality worldwide, the utilization of radiation therapy as a crucial treatment modality is rising. As more individuals undergo radiation therapy for various cancer types, the prevalence of radiodermatitis, a common side effect, also escalates. This heightened demand for radiodermatitis management solutions, including skincare products and treatments, propels market growth, driving innovation and investment in this sector.

Restraint:

High treatment costs

The expenses associated with managing radiodermatitis, including medications, skincare products, and supportive care, impose a financial burden on patients. Additionally, the cumulative costs of radiation therapy sessions exacerbate the economic strain. For many patients, especially those without adequate insurance coverage or financial resources, the affordability of treatments becomes a significant concern. This barrier may limit access to optimal care and adherence to treatment regimens, impacting overall patient outcomes and market growth.

Opportunity:

Growing healthcare infrastructure

Improved healthcare facilities, particularly in emerging economies, enhance access to diagnosis, treatment, and supportive care for radiodermatitis patients. With the establishment of specialized clinics, radiation oncology centers, and dermatology services, individuals can receive timely and comprehensive management for radiodermatitis. Moreover, enhanced infrastructure fosters research and development activities, facilitating the introduction of innovative treatment modalities and skincare products, ultimately driving market growth and improving patient outcomes.

Threat:

Alternative therapies

Alternative therapies pose a threat to the radiodermatitis market as they offer perceived natural or non-pharmaceutical remedies for managing skin-related side effects of radiation therapy. These therapies, ranging from herbal remedies to homeopathic treatments, may attract patients seeking gentler or more holistic approaches. Consequently, they can divert attention and demand away from conventional medical interventions and pharmaceutical products, impacting their competitiveness and market growth.

Covid-19 Impact:

The COVID-19 pandemic has impacted the radiodermatitis market by disrupting healthcare services, delaying non-urgent treatments, and shifting focus towards managing the virus. This has led to a temporary slowdown in radiodermatitis diagnosis and treatment procedures. However, as healthcare systems stabilize and prioritize cancer care, the market is expected to rebound, driven by pent-up demand and ongoing advancements in radiodermatitis management.

The topical segment is expected to be the largest during the forecast period

During the forecast period, the topical segment is poised to emerge as the largest in the radiodermatitis market. This prominence is fueled by various factors, such as the convenience of topical treatments, their ease of application, and their effectiveness in managing radiodermatitis symptoms. Moreover, advancements in topical formulations, including the development of novel compounds and delivery systems, are enhancing their therapeutic efficacy. With an increasing focus on patient comfort and adherence, the demand for topical treatments is expected to witness substantial growth in the coming years.

The online pharmacy segment is expected to have the highest CAGR during the forecast period

The online pharmacy segment is forecasted to experience lucrative growth in the radiodermatitis market during the projected period. This surge is primarily driven by the increasing adoption of e-commerce platforms for purchasing pharmaceutical products. Factors such as convenience, accessibility, and a wide range of product options contribute to the segment's rapid growth. Additionally, the growing trend of telemedicine and digital healthcare services further propels the demand for radiodermatitis treatments through online pharmacies, fostering market expansion.

Region with largest share:

The Asia Pacific is projected to hold the highest market share in the vaccine adjuvant market due to its large population, increasing prevalence of infectious diseases, and rising awareness about vaccination benefits. Additionally, government initiatives and investments in healthcare infrastructure, coupled with the presence of key market players and an expanding biopharmaceutical industry, contribute to market growth. The region's focus on innovative research and development, along with favorable regulatory environments, further drives the demand in Asia Pacific region.

Region with highest CAGR:

The Asia Pacific region is anticipated to exhibit the highest CAGR in the radiodermatitis market over the forecast period. This projection is attributed to several factors, including rising cancer incidence, increased adoption of radiation therapy, expanding healthcare infrastructure, and growing awareness about radiodermatitis management. Additionally, advancements in healthcare technology and government initiatives to improve cancer care are expected to drive market growth in this region.

Key players in the market

Some of the key players in Radiodermatitis Market include 3M Company, Acelity L.P. Inc., Alliqua Biomedical, Inc., B. Braun Melsungen AG, BMG Pharma S.p.A., Cardinal Health, Inc., Coloplast A/S, Convatec Group Plc, DermaRite Industries, LLC, GlaxoSmithKline plc, Hollister Incorporated, Integra Lifesciences Holdings Corporation, Medline Industries, Inc., MiMedx Group, Inc., Molnlycke Health Care AB, Pfizer Inc., Radiation Products Design Inc., Smith & Nephew plc, and Stratpharma AG.

Key Developments:

In May 2024, 3M has cut the ribbon on a new 90,000-square-foot expansion at the company's facility in Valley, Nebraska that will increase the plant's manufacturing capacity and add new jobs to the community. The $67 million investment includes new production lines, equipment and a warehouse, and will help 3M more quickly meet customer demand for the company's personal safety products. The expansion of the plant is expected to create about 40 new jobs.

In January 2024, Cardinal Health announced that it has entered into a definitive agreement to acquire Specialty Networks, a technology-enabled multi-specialty group purchasing and practice enhancement organization for $1.2B in cash. Specialty Networks creates clinical and economic value for independent specialty providers and partners across multiple specialty GPOs: UroGPO, Gastrologix and GastroGPO, and United Rheumatology.

Products Covered:

  • Topical
  • Oral Drugs
  • Dressings

Stages Covered:

  • Mild
  • Moderate
  • Severe

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Radiodermatitis Market, By Product

  • 5.1 Introduction
  • 5.2 Topical
    • 5.2.1 Corticosteroids
    • 5.2.2 Hydrophilic Creams
    • 5.2.3 Topical Antibiotics
    • 5.2.4 Other Topicals
  • 5.3 Oral Drugs
  • 5.4 Dressings
    • 5.4.1 Honey Impregnated Gauze
    • 5.4.2 Hydrocolloid Dressings
    • 5.4.3 Hydrogel Dressings
    • 5.4.4 No Sting Barrier Film
    • 5.4.5 Silicone Coated Dressings
    • 5.4.6 Other Dressings

6 Global Radiodermatitis Market, By Stage

  • 6.1 Introduction
  • 6.2 Mild
  • 6.3 Moderate
  • 6.4 Severe

7 Global Radiodermatitis Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Online Pharmacies

8 Global Radiodermatitis Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 3M Company
  • 10.2 Acelity L.P. Inc.
  • 10.3 Alliqua Biomedical, Inc.
  • 10.4 B. Braun Melsungen AG
  • 10.5 BMG Pharma S.p.A.
  • 10.6 Cardinal Health, Inc.
  • 10.7 Coloplast A/S
  • 10.8 Convatec Group Plc
  • 10.9 DermaRite Industries, LLC
  • 10.10 GlaxoSmithKline plc
  • 10.11 Hollister Incorporated
  • 10.12 Integra Lifesciences Holdings Corporation
  • 10.13 Medline Industries, Inc.
  • 10.14 MiMedx Group, Inc.
  • 10.15 Molnlycke Health Care AB
  • 10.16 Pfizer Inc.
  • 10.17 Radiation Products Design Inc.
  • 10.18 Smith & Nephew plc
  • 10.19 Stratpharma AG

List of Tables

  • Table 1 Global Radiodermatitis Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Radiodermatitis Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Radiodermatitis Market Outlook, By Topical (2022-2030) ($MN)
  • Table 4 Global Radiodermatitis Market Outlook, By Corticosteroids (2022-2030) ($MN)
  • Table 5 Global Radiodermatitis Market Outlook, By Hydrophilic Creams (2022-2030) ($MN)
  • Table 6 Global Radiodermatitis Market Outlook, By Topical Antibiotics (2022-2030) ($MN)
  • Table 7 Global Radiodermatitis Market Outlook, By Other Topicals (2022-2030) ($MN)
  • Table 8 Global Radiodermatitis Market Outlook, By Oral Drugs (2022-2030) ($MN)
  • Table 9 Global Radiodermatitis Market Outlook, By Dressings (2022-2030) ($MN)
  • Table 10 Global Radiodermatitis Market Outlook, By Honey Impregnated Gauze (2022-2030) ($MN)
  • Table 11 Global Radiodermatitis Market Outlook, By Hydrocolloid Dressings (2022-2030) ($MN)
  • Table 12 Global Radiodermatitis Market Outlook, By Hydrogel Dressings (2022-2030) ($MN)
  • Table 13 Global Radiodermatitis Market Outlook, By No Sting Barrier Film (2022-2030) ($MN)
  • Table 14 Global Radiodermatitis Market Outlook, By Silicone Coated Dressings (2022-2030) ($MN)
  • Table 15 Global Radiodermatitis Market Outlook, By Other Dressings (2022-2030) ($MN)
  • Table 16 Global Radiodermatitis Market Outlook, By Stage (2022-2030) ($MN)
  • Table 17 Global Radiodermatitis Market Outlook, By Mild (2022-2030) ($MN)
  • Table 18 Global Radiodermatitis Market Outlook, By Moderate (2022-2030) ($MN)
  • Table 19 Global Radiodermatitis Market Outlook, By Severe (2022-2030) ($MN)
  • Table 20 Global Radiodermatitis Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 21 Global Radiodermatitis Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 22 Global Radiodermatitis Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 23 Global Radiodermatitis Market Outlook, By Online Pharmacies (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.